🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05858944
Recruiting Not applicable

Home Blood Pressure Intervention in the Community Trial

NCT05858944 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Institute of Hypertension
Phase
Not applicable
Started
2023-05-06
Last updated
2025-01-06

Condition(s) studied

Home Blood Pressure

Investigational drug(s) / intervention(s)

Intensive Home BP controlStandard Home BP control

Intensive Home BP control: If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.

Standard Home BP control: If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.

Study summary

The primary purpose of the study is to explore whether a lower home blood pressure target (125/75 v.s. 135/85 mmHg) would be beneficial to elderly treated hypertensive patients in terms of reduced incidence of cardiovascular events. The study also aims to promote the application of standardised and information-based home blood pressure monitoring in community hypertension management.

Eligibility

Sex
ALL
Min age
60 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 60-80 years old * Have been taking antihypertensive drugs for more than 2 weeks * The average SBP and/or DBP of 7-day home blood pressure monitoring ≥135/85 mmHg * Willing to participate, adhere to follow-up, and sign the written informed consent form Exclusion Criteria: * Arm circumference too large or too small (less than 18 cm or greater than 42 cm) to fit the cuff in case of inaccurate measurement * Invalid home blood pressure monitoring. The valid home blood pressure monitoring requires consecutive measurements for at least 3 days, with not less than 1 measurement in the morning and evening, respectively. * Office blood pressure indicates stage 3 clinic hypertension (≥180/110 mmHg) during the screening period * Suspected or known secondary hypertension * Orthostatic hypotension, defined as a decrease in systolic blood pressure greater than 20 mmHg or diastolic blood pressure greater than 10 mmHg within 3 minutes when position is changed from sitting to standing * eGFR\<30 ml/min/1.73m2 or end-stage renal disease * Cardiovascular events occured within the past 3 months, such as myocardial infarction, stroke, acute heart failure, hospitalization for unstable angina, undergoing coronary artery revascularization or bypass grafting * Abnormal liver function (ALT/AST/total bilirubin more than 2 times the upper limit of normal value) * Severe somatic disease with a life expectancy of less than 3 years, or diagnosed with cancer within the past 2 years requiring treatment * Doctors deem that the participation would do harm to the patients or the patients would have poor compliance.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Community hospitals Shanghai Shanghai Municipality Recruiting

More Shanghai Institute of Hypertension trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05858944 on ClinicalTrials.gov ↗ ← All trials in China